GILD Gilead Sciences, Inc.
76,486
$65.89
$1.31
(2.03%)
| Watchers | 76,486 |
| 52-Wk Low | $64.33 |
| 52-Wk High | $87.87 |
| Market Cap | $80.53B |
| Volume | 5.78M |
| 52-Wk High | $87.87 |
| 52-Wk Low | $64.33 |
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramBusiness Wire • about 23 hours ago
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma...
Share to Feed
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma...
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 14 at 11:20am...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. Gilead delivered another strong quarter of revenue growth in the first quarter with 6...
Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore
Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...